Version June 2024
This algorithm pertains to average-risk patients. Patients with a hereditary ovarian cancer syndrome (eg, BRCA mutation, Lynch syndrome) are managed differently; for more information, refer to UpToDate content on hereditary ovarian cancer syndromes.
Imaging typically includes pelvic ultrasound (transvaginal and transabdominal); for masses with an indeterminant appearance on ultrasound, MRI or CT may be used as a secondary imaging study.
The O-RADS classification system is detailed separately in related UpToDate topics.O-RADS: Ovarian-Adnexal Reporting and Data System; CA 125: cancer antigen 125; BRCA: breast cancer susceptibility genes; MRI: magnetic resonance imaging; CT: computed tomography.
* Surgical management (cystectomy versus oophorectomy) depends on clinical suspicion for malignancy; if malignancy is found, surgical management depends on disease stage and desire for future childbearing.
¶ Tumor markers (eg, CA 125) may be obtained preoperatively to help guide management.
Δ Surgical management may be performed in patients who desire removal of the mass, even in the absence of findings or symptoms suggestive of malignancy.
◊ CA 125 levels are obtained at each ultrasound examination if the initial level is moderately elevated (35 to <200 U/mL) until a trend is established; if it is consistently low or moderately elevated, we discontinue CA 125 testing.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
